A major new trial is to begin next month aimed at improving the treatment for cardiogenic shock.
The EURO-SHOCK trial, funded by the European Union’s Horizon 2020 Research and Innovation programme, will investigate the early application of extra-corporeal membrane oxygenation (ECMO) to reduce mortality associated with cardiogenic shock.
The last major breakthrough in this area dates back almost 2 decades when it was shown that the prognosis could be improved by urgent re-opening of the occluded coronary artery that causes the myocardial infarction and led to cardiogenic shock. However, the investigators say despite several recent attempts, no significant improvement in mortality has yet been achieved.
This new trial will involve 12 university hospitals in 9 countries. Patients will receive immediate revascularisation. Following consent, they will be randomised to receive standard treatment with or without ECMO in the first few hours after the diagnosis of cardiogenic shock.
Investigators hope to recruit more than 400 patients to the trial over a 34-month period, beginning from 1 February.